Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01952444 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability and PK of Intravenous (IV) ETI-204 Alone and in Presence of Ciprofloxacin in Adult Volunteers
A Phase 1 study, sponsored by Elusys Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT01952444 is a Phase 1 study that has completed, run by Elusys Therapeutics. The registered enrollment target is 40 participants.
The verdict
NCT01952444, a Phase 1 study, has completed, sponsored by Elusys Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
Evaluate the safety, tolerability and pharmacokinetics (PK) of intravenous (IV) ETI-204 alone and in the presence of IV and oral ciprofloxacin
Interventions
- DRUG Ciprofloxacin
- BIOLOGICAL ETI-204
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2013-10-29 |
| Est. Completion | 2014-04-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01952444
The ClinicalTrials.gov registry entry for NCT01952444 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Elusys Therapeutics, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ciprofloxacin is the first listed.
NCT01952444 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01952444 about?
NCT01952444 is a clinical study titled "Safety, Tolerability and PK of Intravenous (IV) ETI-204 Alone and in Presence of Ciprofloxacin in Adult Volunteers". Evaluate the safety, tolerability and pharmacokinetics (PK) of intravenous (IV) ETI-204 alone and in the presence of IV and oral ciprofloxacin
What is the current status of trial NCT01952444?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2013-10-29. Estimated completion is 2014-04-09.
What interventions are being tested in trial NCT01952444?
The interventions under investigation include: Ciprofloxacin (DRUG), ETI-204 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01952444?
This trial is sponsored by Elusys Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.